Vincristine-induced vocal cord palsy and successful re-treatment in a patient with diffuse large B cell Lymphoma: a case report
© Samoon and Shabbir-Moosajee; licensee BioMed Central Ltd. 2014
Received: 9 December 2013
Accepted: 26 May 2014
Published: 27 May 2014
Vincristine, a type of vinca alkaloid, is widely used in the treatment of various childhood and adult malignancies. A well-known side effect of vincristine is its neurotoxicity and it is rarely indicted in vagus nerve involvement. Vincristine induced vocal cord palsy is a potentially reversible condition, with the mainstay of therapy being withdrawal of the offending drug. However, there are no clear guidelines regarding the possibility of re-treatment with the causative agent.
A 58 year old Asian male presented with constipation and abdominal distension. Diagnostic investigations revealed stage IVB diffuse large B cell lymphoma (DLBCL). The patient was subsequently started on R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone). On day twelve of receiving course four of R-CHOP, our patient presented to the hospital with a history of hoarseness of voice. Clinical and radiological examination revealed bilateral vocal cord palsy. Tracheostomy was done in view of a compromised airway. The patient subsequently went on to receive two more cycles of R-CHOP. Two weeks later Flexible laryngoscopy showed no lesion and the vocal cords were moving normally. The tracheostomy was removed. His voice has improved since and the patient is currently in remission.
The occurrence of vincristine induced vocal cord palsy has been well reported in the literature. We strongly believe that our patient developed vocal cord palsy secondary to vincristine. The uniqueness of our patient’s case lies in successful re-treatment of our patient with the offending drug. To the best of our knowledge this is the third instance where a patient was successfully re-treated with vincristine after having developed vocal cord palsy as a result of its use.
Vincristine, a type of vinca alkaloid, is widely used in the treatment of various childhood and adult malignancies. Peripheral neuropathy is a well-known and recognized side effect of this drug. However, there atypical neurotoxic manifestations of vincristine, some of which may be fatal. Early recognition of such neurological complications and their prompt management may lead to complete recovery.
We present a case of a fifty eight year old man receiving R-CHOP for DLBCL who suddenly developed bilateral vocal cord palsy secondary to vincristine induced neurotoxicity. He had spontaneous recovery of neurological function despite continuation of the drug.
Fiber-optic laryngoscopy was performed, which showed swelling in the posterior part of right vocal cord, both vocal cords fixed with a narrow glottic opening. Tracheostomy was done in view of a compromised airway. Intra-operatively, the right vocal cord appeared inflamed and was biopsied. Biopsy revealed severe acute and chronic inflammation with no evidence of malignancy.
The patient was discharged from hospital and continued antibiotics outpatient. Subsequently flexible laryngoscopy showed left vocal cord moving normally and right vocal cord showing limited movement. The patient then received two more courses of R-CHOP till January 2013, with full dose of vincristine, as the main differential for vocal cord palsy was mainly infection. The vocal cords had not regained normal function till that point in time.
Two weeks after completion of therapy flexible laryngoscopy showed no lesion and the vocal cords were moving normally. The tracheostomy was removed. His voice has improved since. A positron emission tomogram done after six courses of R-CHOP show no residual disease and to date he remains disease free.
Rituximab with CHOP like chemotherapy is the standard of care in patients with diffuse large B cell lymphoma of which vincristine is an essential component [1, 2]. Vincristine is known to cause various side effects such as constipation, hair loss, hyponatremia however neurotoxicity is the most common amongst them . Vincristine is postulated to interfere with microtubule formation and cause axonal degeneration . Factors leading to more severe neurotoxicity include hypersensitivity to the drug, pre-existing liver dysfunction, hereditary neuropathy, and concomitant use of certain drugs, such as allopurinol, erythromycin, isoniazid, mitomycin, phenytoin and itraconazole [5, 6]. Vincristine induced neurotoxicity can present as a mixed sensorimotor neuropathy, autonomic dysfunction and less commonly cranial nerve involvement and encephalopathy. The cranial nerve involvement can be present as transient cortical blindness, hearing loss, facial palsy, occulomotor nerve dysfunction, jaw pain as a manifestation of trigeminal neuropathy, facial palsy and rarely recurrent laryngeal nerve palsy which can result in vocal cord palsy [7, 8]. Vocal cord paralysis can be due to peripheral damage to the laryngeal nerve or to the vagus nerve nuclei and its origin within the central nervous system . Bilateral involvement is usually due to involvement of the vagal nuclei while unilateral involvement is believed to be due to peripheral damage of the vagus nerve .
Vincristine induced vocal cord palsy has mainly been reported in the pediatrics age group, with few case reports in adult. Its prevalence is said to about 1.36% in pediatric patients . From literature review it is evident that vincristine induced neuropathy is related to dose intensity along with cumulative dose effect . In most patients, vincristine induced vocal cord palsy occurs beyond its second dose.
There is no specific treatment of vincristine induced vocal cord palsy. Pyridoxine and pyridostigmine has been associated with an early recovery (within 1–2 weeks) of vincristine induced peripheral neuropathy in a case series of patients . The role of glutamic acid in decreasing vincristine induced neurotoxicity has been analyzed in some studies involving rat model , however this was not found to be effective when used in a patient with vincristine induced vocal cord palsy . Overall about 55-66% of all pediatrics patients presenting with bilateral vocal cord paralysis require airway protection with a tracheostomy . In a case series of 10 pediatrics patients with vincristine induced bilateral vocal cord palsy, only 2 required tracheostomy . Vincristine induced vocal cord palsy may be reversible and complete recovery occurs in 6–9 months [6, 7, 15].
Literature review of cases of Vincristine-Induced Laryngeal Paralysis (VLP) in whom full dose of vincristine was re-administered
Duration of paralysis
Administration of vincristine
Ahmed et al. 
Acute lymphoblastic leukemia
Redeveloped hoarseness on receiving full dose. VCR Ommited
Kuruvilla et al. 
Rhabdomyosarcoma of testicles
Gradually received complete dose.
Acute lymphoblastic leukemia
Redeveloped hoarseness on receiving full dose. Dose reduced to 1/3rd subsequently
Burns et al. 
Received full dose uneventfully.
In conclusion, we report a case of vincristine induced bilateral recurrent laryngeal nerve palsy who had full recovery of vocal cord palsy within two weeks after completion of definitive treatment of diffuse large B cell lymphoma. We think that vincristine induced vocal cord palsy is potentially reversible and careful protection of airway is needed when completion of treatment is the goal.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
ZS did the literature search and drafted the manuscript. MSM conceived the case report and helped in drafting the manuscript. Both authors read and approved the final manuscript.
We would like to thank Dr. Tayyaba Z. Ansari who provided important intellectual input during the drafting phase of the manuscript.
The authors did not receive any research support for this manuscript and do not have any financial disclosures to make.
- Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010, 116 (12): 2040-2045. 10.1182/blood-2010-03-276246.PubMedPubMed CentralView ArticleGoogle Scholar
- Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011, 12 (11): 1013-1022. 10.1016/S1470-2045(11)70235-2.PubMedView ArticleGoogle Scholar
- Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol. 2002, 249 (1): 9-17. 10.1007/PL00007853.PubMedView ArticleGoogle Scholar
- Bradley WG, Lassman LP, Pearce GW, Walton JN: The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970, 10 (2): 107-131. 10.1016/0022-510X(70)90013-4.PubMedView ArticleGoogle Scholar
- Chan JD: Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy. 1998, 18 (6): 1304-1307.PubMedGoogle Scholar
- Jeng MR, Feusner J: Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001, 18 (2): 137-142. 10.1080/088800101300002973.PubMedView ArticleGoogle Scholar
- Anghelescu DL, De Armendi AJ, Thompson JW, Sillos EM, Pui CH, Sandlund JT: Vincristine-induced vocal cord paralysis in an infant. Paediatr Anaesth. 2002, 12 (2): 168-170. 10.1046/j.1460-9592.2002.00816.x.PubMedView ArticleGoogle Scholar
- Annino DJ, MacArthur CJ, Friedman EM: Vincristine-induced recurrent laryngeal nerve paralysis. Laryngoscope. 1992, 102 (11): 1260-1262. 10.1288/00005537-199211000-00011.PubMedView ArticleGoogle Scholar
- Tobias JD, Bozeman PM: Vincristine-induced recurrent laryngeal nerve paralysis in children. Intensive Care Med. 1991, 17 (5): 304-305. 10.1007/BF01713944.PubMedView ArticleGoogle Scholar
- Latiff ZA, Kamal NA, Jahendran J, Alias H, Goh BS, Syed Zakaria SZ, Jamal R: Vincristine-induced vocal cord palsy: case report and review of the literature. J Pediatr Hematol Oncol. 2010, 32 (5): 407-410. 10.1097/MPH.0b013e3181e01584.PubMedView ArticleGoogle Scholar
- Kuruvilla G, Perry S, Wilson B, El-Hakim H: The natural history of vincristine-induced laryngeal paralysis in children. Arch Otolaryngol Head Neck Surg. 2009, 135 (1): 101-105. 10.1001/archoto.2008.514.PubMedView ArticleGoogle Scholar
- Akbayram S, Akgun C, Dogan M, Sayin R, Caksen H, Oner AF: Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy. Indian J Pediatr. 2010, 77 (6): 681-683. 10.1007/s12098-010-0096-z.PubMedView ArticleGoogle Scholar
- Boyle FM, Wheeler HR, Shenfield GM: Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther. 1996, 279 (1): 410-415.PubMedGoogle Scholar
- Farruggia P, Tropia S, Cannella S, Bruno G, Oddo G, D'Angelo P: Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report. J Med Case Rep. 2012, 6 (1): 128-10.1186/1752-1947-6-128.PubMedPubMed CentralView ArticleGoogle Scholar
- Whittaker JA, Griffith IP: Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. Br Med J. 1977, 1 (6071): 1251-1252. 10.1136/bmj.1.6071.1251.PubMedPubMed CentralView ArticleGoogle Scholar
- Ahmed A, Williams D, Nicholson J: Vincristine-induced bilateral vocal cord paralysis in children. Pediatr Blood Cancer. 2007, 48 (2): 248-10.1002/pbc.20850.PubMedView ArticleGoogle Scholar
- Burns BV, Shotton JC: Vocal fold palsy following vinca alkaloid treatment. J Laryngol Otol. 1998, 112 (5): 485-487.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.